AK
Akari Therapeutics, Plc
AKTX · NASDAQ
$11.77 +8.78% (+$0.95)
1M +63.86%
Market Cap $13.0M
P/E Ratio -
Div. Yield -
ROE 147.45%
Bulios Fair Price
$16.47
39.9% upside
Trenutna cena
$11.77
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica AKTX trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.70x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 151.02%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 115.17%
ROE 147.45%
ROA 80.16%
Debt
49 /100
Moderate Debt/Equity 0.04x
Current ratio 0.60x
Int. coverage -32.09x
Stability
43 /100
Moderate Beta 1.39x
EPS volatility 33.66%
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o AKTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Abizer Gaslightwala
Employees
6
Headquarters
Tampa
Prihajajoči dogodki
04 DEC.
Earnings
Upcoming earnings report